The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Insights into the safety and efficacy of belantamab mafodotin in systemic AL amyloidosis
Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses the safety and efficacy of belantamab mafodotin in relapsed light chain (AL) amyloidosis. Whilst this agent has been associated with ocular toxicity in multiple myeloma, when given in decreased doses and at intervals of four to six weeks, it proved efficacious against systemic AL amyloidosis, with ocular toxicity being reversible. How this agent will be included in the current treatment landscape remains to be seen. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
